Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,241.20
(
-1.16%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
107.19
(
-1.28%
)
Bitcoin
67,654.84
(
1.43%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Sunday, 04/30/2006 6:07:24 PM

Sunday, April 30, 2006 6:07:24 PM

Post# of 257314
Survey on the Future of HCV Treatment

Five years from now, the standard regimen in treatment-naïve HCV will be:

a) VX-950 monotherapy;
b) Some monotherapy other than VX-950;
c) An all-oral (no interferon) cocktail;
d) A cocktail including interferon and one oral drug;
e) A cocktail including interferon and two or more oral drugs.

To vote, please go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #59.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today